• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雄激素受体的翻译后修饰。

Post-translational modification of the androgen receptor.

机构信息

Department of Microbiology, University of Virginia, Charlottesville, Virginia, USA.

出版信息

Mol Cell Endocrinol. 2012 Apr 16;352(1-2):70-8. doi: 10.1016/j.mce.2011.07.004. Epub 2011 Jul 24.

DOI:10.1016/j.mce.2011.07.004
PMID:21820033
Abstract

Regulation of the androgen receptor (AR) by its cognate ligand is well established, but how post-translational modification modulates AR activity is only emerging. The AR is subject to modification by phosphorylation, acetylation, methylation, SUMOylation, and ubiquitination. As several of the enzymes that modify the AR are altered in prostate cancer, defining the context and physiological effects of these modifications could provide insight into mechanisms that underpin human disease. Here, we review how post-translational modification contributes to AR function as a transcription factor with particular emphasis on phosphorylation and dephosphorylation mechanisms.

摘要

雄激素受体(AR)与其同源配体的调节作用已得到充分证实,但翻译后修饰如何调节 AR 活性尚在研究之中。AR 可发生磷酸化、乙酰化、甲基化、SUMO 化和泛素化等翻译后修饰。由于几种修饰 AR 的酶在前列腺癌中发生了改变,因此确定这些修饰的作用背景和生理效应可以深入了解支持人类疾病的机制。在这里,我们回顾了翻译后修饰如何作为转录因子促进 AR 功能,特别强调了磷酸化和去磷酸化机制。

相似文献

1
Post-translational modification of the androgen receptor.雄激素受体的翻译后修饰。
Mol Cell Endocrinol. 2012 Apr 16;352(1-2):70-8. doi: 10.1016/j.mce.2011.07.004. Epub 2011 Jul 24.
2
Posttranslational modification of the androgen receptor in prostate cancer.前列腺癌中雄激素受体的翻译后修饰。
Int J Mol Sci. 2013 Jul 16;14(7):14833-59. doi: 10.3390/ijms140714833.
3
Regulating Androgen Receptor Function in Prostate Cancer: Exploring the Diversity of Post-Translational Modifications.调控前列腺癌中的雄激素受体功能:探索翻译后修饰的多样性
Cells. 2024 Jan 19;13(2):191. doi: 10.3390/cells13020191.
4
Post-translational modifications of nuclear receptors and human disease.核受体的翻译后修饰与人类疾病
Nucl Recept Signal. 2012;10:e001. doi: 10.1621/nrs.10001. Epub 2012 Feb 27.
5
Regulation of the androgen receptor by post-translational modifications.雄激素受体的翻译后修饰调节。
J Endocrinol. 2012 Nov;215(2):221-37. doi: 10.1530/JOE-12-0238. Epub 2012 Aug 7.
6
SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.小泛素样修饰特异性蛋白酶1(SENP1)可逆转激素增强的雄激素受体小泛素样修饰,并调节前列腺癌细胞中的基因反应。
Mol Endocrinol. 2009 Mar;23(3):292-307. doi: 10.1210/me.2008-0219. Epub 2008 Dec 30.
7
ARD1/NAA10 acetylation in prostate cancer.前列腺癌中的 ARD1/NAA10 乙酰化。
Exp Mol Med. 2018 Jul 27;50(7):1-8. doi: 10.1038/s12276-018-0107-0.
8
Acetylation of androgen receptor by ARD1 promotes dissociation from HSP90 complex and prostate tumorigenesis.ARD1介导的雄激素受体乙酰化促进其与热休克蛋白90复合物解离并推动前列腺肿瘤发生。
Oncotarget. 2016 Nov 1;7(44):71417-71428. doi: 10.18632/oncotarget.12163.
9
The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity.雄激素受体乙酰化位点调节cAMP和AKT,但不调节ERK诱导的活性。
J Biol Chem. 2004 Jul 9;279(28):29436-49. doi: 10.1074/jbc.M313466200. Epub 2004 Apr 30.
10
Androgen receptor post-translational modifications and their implications for pathology.雄激素受体的翻译后修饰及其对病理学的影响。
Biochem Soc Trans. 2024 Aug 28;52(4):1673-1694. doi: 10.1042/BST20231082.

引用本文的文献

1
Apolipoprotein E promotes primary resistance to AR-targeted therapy via inducing TRIM25-mediated AR ubiquitination and sensitizes immunotherapy in prostate cancer.载脂蛋白E通过诱导TRIM25介导的雄激素受体泛素化促进对雄激素受体靶向治疗的原发性耐药,并使前列腺癌的免疫治疗敏感化。
Theranostics. 2025 Apr 21;15(12):5572-5591. doi: 10.7150/thno.109994. eCollection 2025.
2
Identification of pyrimidine metabolism-based molecular subtypes and prognostic signature to predict immune landscape and guide clinical treatment in prostate cancer.基于嘧啶代谢的前列腺癌分子亚型鉴定及预后特征预测免疫格局并指导临床治疗
Ann Med. 2025 Dec;57(1):2449584. doi: 10.1080/07853890.2025.2449584. Epub 2025 Jan 13.
3
CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
CDK9抑制作用可抑制前列腺癌中的多种致癌转录和表观遗传途径。
Br J Cancer. 2024 Oct;131(6):1092-1105. doi: 10.1038/s41416-024-02810-8. Epub 2024 Aug 8.
4
MDM2 regulates the stability of AR, AR-V7, and TM4SF3 proteins in prostate cancer.MDM2调节前列腺癌中雄激素受体(AR)、AR-V7和TM4SF3蛋白的稳定性。
Endocr Oncol. 2024 Feb 9;4(1):e230017. doi: 10.1530/EO-23-0017. eCollection 2024 Jan 1.
5
Inhibition of N-myristoyltransferase activity promotes androgen receptor degradation in prostate cancer.抑制 N-豆蔻酰转移酶活性可促进前列腺癌中雄激素受体的降解。
Prostate. 2024 Feb;84(3):254-268. doi: 10.1002/pros.24645. Epub 2023 Oct 31.
6
YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy.YIV-818-A:一种通过下调雄激素受体、抑制糖皮质激素受体、进行表观遗传调控以及增强阿帕鲁胺、达罗他胺和恩杂鲁胺疗效来治疗前列腺癌的新型治疗药物。
Front Pharmacol. 2023 Oct 4;14:1244655. doi: 10.3389/fphar.2023.1244655. eCollection 2023.
7
A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance.雄激素受体二聚体界面上翻译后修饰的热点导致了病理和抗雄激素耐药性。
Sci Adv. 2023 Mar 17;9(11):eade2175. doi: 10.1126/sciadv.ade2175. Epub 2023 Mar 15.
8
Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo.转移性去势抵抗性前列腺癌中的耐药性:现状更新
Cancer Drug Resist. 2022 Jun 22;5(3):667-690. doi: 10.20517/cdr.2022.15. eCollection 2022.
9
Exploring the Role of Posttranslational Modifications in Spinal and Bulbar Muscular Atrophy.探索翻译后修饰在脊髓延髓肌萎缩症中的作用。
Front Mol Neurosci. 2022 Jun 3;15:931301. doi: 10.3389/fnmol.2022.931301. eCollection 2022.
10
Leukemia inhibitory factor receptor homodimerization mediated by acetylation of extracellular lysine promotes prostate cancer progression through the PDPK1/AKT/GCN5 axis.乙酰化修饰细胞外赖氨酸介导白血病抑制因子受体同源二聚化促进前列腺癌进展的机制研究。该过程通过 PDPK1/AKT/GCN5 轴发挥作用。
Clin Transl Med. 2022 Feb;12(2):e676. doi: 10.1002/ctm2.676.